Law W M, Bollman S, Kumar R, Heath H
J Clin Endocrinol Metab. 1984 Apr;58(4):744-7. doi: 10.1210/jcem-58-4-744.
We compared serum concentrations of immunoreactive PTH and plasma levels of vitamin D metabolites in 11 patients with adenomatous primary hyperparathyroidism and 32 individuals with the syndrome of familial benign hypercalcemia or familial hypocalciuric hypercalcemia (FHH). Serum immunoreactive PTH was elevated in the hyperparathyroid group but indistinguishable from control in FHH, despite comparable degrees of hypercalcemia. Plasma 25-hydroxyvitamin D concentrations were normal in both groups, but plasma 1,25-dihydroxyvitamin D levels in FHH were significantly lower than control (P less than 0.0025) or hyperparathyroid (P less than 0.01) values. FHH is pathogenetically distinct from primary hyperparathyroidism and should not be thought of simply as a variant of that condition.
我们比较了11例腺瘤性原发性甲状旁腺功能亢进患者与32例患有家族性良性高钙血症或家族性低钙尿性高钙血症(FHH)综合征个体的血清免疫反应性甲状旁腺激素(PTH)浓度和血浆维生素D代谢产物水平。甲状旁腺功能亢进组血清免疫反应性PTH升高,但在FHH中与对照组无差异,尽管高钙血症程度相当。两组血浆25-羟维生素D浓度均正常,但FHH组血浆1,25-二羟维生素D水平显著低于对照组(P<0.0025)或甲状旁腺功能亢进组(P<0.01)。FHH在发病机制上与原发性甲状旁腺功能亢进不同,不应简单地被视为该病的一种变体。